20 Novembre 2026

Psicologia Punto One | Psicologia e Psicologi nel Web

Menu

Menu

SCHEDA SCIENTIFICA2026Studio osservazionale

Comorbidities in individuals with intellectual disabilities with and without hearing loss: a prospective cohort study.

Awa Naghipour, Corinna Gietmann, Vincent Jankovic, Martin Scharpenberg, Susanna Marie Zielonkowski, Lukas Prein, Katharina Schwarze, Anja Neumann, Susanne Wasmuth, Karolin Schäfer, Christian Speckemeier, Sarah Schlierenkamp, Sandra Werner, Ross Parfitt, Anna Wiegand, Anna-Sophia Schwalen, Werner Brannath, Philipp Mathmann, Katrin Neumann

BMC public health · 2026

Abstract originale

BACKGROUND: Both intellectual disability (ID) and hearing loss (HL) are associated with a high prevalence of certain comorbidities. However, a combined analysis and overview classified according to the International Classification of Diseases, 11th Revision (ICD-11), is lacking. HL is disproportionately common among individuals with ID and often remains undetected. We evaluated: (1) which comorbidities are most common in ID; (2) how disease prevalence differs between those with and without HL; (3) whether the degree of ID or HL influences the number of additional diseases, surgeries, or medication intake. METHODS: This study is part of a prospective cohort study investigating effectiveness and feasibility of repeated universal hearing screenings and interventions for people with ID. We included 1,053 participants with ID (37% female, 63% male, and < 1% intersex; age range 1-90 years). Medical history assessment and on-site hearing testing were combined. Diseases were ICD-11-coded. Descriptive statistics and binary logistic regression models assessed associations between common diseases and age, sex, HL, and ID. RESULTS: Nearly all comorbidities observed in participants with HL (prevalence > 5% [= 14]) were more frequent in participants with HL vs. without (13/14), eight showing odds ratios [OR] and 95% confidence interval [CI] > 1: visual impairment; hypertension; trisomy 21; obesity; mental, behavioural, or neurodevelopmental disorders; spinal conditions; diabetes; hypothyroidism. Logistic regression underscored associations between: (1) HL and visual impairment, trisomy 21, spinal conditions, hypothyroidism; (2) age and hypertension, obesity, diabetes; (3) female sex and trisomy 21, hypothyroidism. Epilepsy occurred similarly (OR 1.01, 95% CI: 0.65-1.56) and autism spectrum disorder (ASD) less often in the HL-subcohort (OR 0.42, 95% CI: 0.24-0.73). Trisomy 21 was 3-4 times more frequent in the HL-subcohort, showed a female preponderance and high rates of cardiovascular, metabolic, and visual diseases. Associated comorbidities (mean 2.75 vs 1.65) and multimorbidity (≥ two diseases, 63% vs. 42%) were higher in persons with HL than without, as was medication intake (mean 2.73 vs. 0.84). CONCLUSION: In our study individuals with ID and HL showed increased comorbidity, multimorbidity, and higher medication intake than those without HL. Heightened awareness and individualised, multidisciplinary management are essential in order to ensure equitable care and prevent secondary complications.

Parole chiave

HumansFemaleMaleProspective StudiesIntellectual DisabilityComorbidityAdolescentAdultMiddle AgedChildHearing LossAgedYoung AdultChild, PreschoolAged, 80 and overInfantPrevalenceAgeHealth equityHearing lossICD-11Intellectual disabilityMultidisciplinary careSex
Leggi il testo integrale originale

Testo estratto dalla pubblicazione: sono esclusi immagini, media, supplementi e parti soggette a diritti distinti.

Comorbidities in individuals with intellectual disabilities with and without hearing loss: a prospective cohort study

Background

Both intellectual disability (ID) and hearing loss (HL) are associated with a high prevalence of certain comorbidities. However, a combined analysis and overview classified according to the International Classification of Diseases, 11th Revision (ICD-11), is lacking. HL is disproportionately common among individuals with ID and often remains undetected. We evaluated: (1) which comorbidities are most common in ID; (2) how disease prevalence differs between those with and without HL; (3) whether the degree of ID or HL influences the number of additional diseases, surgeries, or medication intake.

Methods

This study is part of a prospective cohort study investigating effectiveness and feasibility of repeated universal hearing screenings and interventions for people with ID. We included 1,053 participants with ID (37% female, 63% male, and < 1% intersex; age range 1–90 years). Medical history assessment and on-site hearing testing were combined. Diseases were ICD-11-coded. Descriptive statistics and binary logistic regression models assessed associations between common diseases and age, sex, HL, and ID.

Results

Nearly all comorbidities observed in participants with HL (prevalence > 5% [= 14]) were more frequent in participants with HL vs. without (13/14), eight showing odds ratios [OR] and 95% confidence interval [CI] > 1: visual impairment; hypertension; trisomy 21; obesity; mental, behavioural, or neurodevelopmental disorders; spinal conditions; diabetes; hypothyroidism. Logistic regression underscored associations between: (1) HL and visual impairment, trisomy 21, spinal conditions, hypothyroidism; (2) age and hypertension, obesity, diabetes; (3) female sex and trisomy 21, hypothyroidism. Epilepsy occurred similarly (OR 1.01, 95% CI: 0.65–1.56) and autism spectrum disorder (ASD) less often in the HL-subcohort (OR 0.42, 95% CI: 0.24–0.73). Trisomy 21 was 3–4 times more frequent in the HL-subcohort, showed a female preponderance and high rates of cardiovascular, metabolic, and visual diseases. Associated comorbidities (mean 2.75 vs 1.65) and multimorbidity (≥ two diseases, 63% vs. 42%) were higher in persons with HL than without, as was medication intake (mean 2.73 vs. 0.84).

Conclusion

In our study individuals with ID and HL showed increased comorbidity, multimorbidity, and higher medication intake than those without HL. Heightened awareness and individualised, multidisciplinary management are essential in order to ensure equitable care and prevent secondary complications.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12889-026-29321-w.

Introduction

Individuals with intellectual disabilities (ID) comprise approximately 1–2% of the global population, and a similar proportion of the German population, with a slightly higher prevalence reported for males (1.42%) than females (1.37%) [1–3]. Individuals with ID have repeatedly been reported to have a higher proportion of a variety of diseases [3–14], with earlier age of onset [5] and a higher mortality rate [4, 15–19] than in the general population. Alarmingly, Heslop et al. demonstrated that twice as many individuals with ID die of causes that could have been prevented by adequate health care than in the general population [15, 20]. Similarly, Thygesen et al. reported a standardised mortality ratio (SMR) of 2.62 (95% CI, 2.51–2.73) for preventable deaths and 6.00 (5.72–6.29) for treatable causes of death [19]. Individuals with ID also carry a greater risk of unidentified morbidities [21]. Baxter et al. found that 51% of study participants with ID who underwent health checks had newly discovered health needs, 63% of them one, 25% two, and 12% more than two [21].

Hearing loss (HL) poses a specific health challenge for individuals with ID [22]. The prevalence of HL is reported to be higher than in the general population, and systematic gaps in both diagnostics and further care have been found [22, 23].

HL affects approximately 20% of the world's population and 34.5% of the German population, with prevalence increasing with age and further exacerbated by demographic change [22, 24]. The significance of HL is underscored by the fact that, according to the Global Burden of Disease Study 2019, it is the third most common reason for years lived with disability and was ranked first among sensory disorders [24]. In another arm of our study, we found a negative association between severity of HL and hearing-related quality of life [25].

Schrojenstein Lantman-De Valk et al. already found a significantly higher prevalence of sensory impairments in individuals with ID in the year 2000 [12]. They suggested that the limited communication abilities of individuals with ID are further compromised when sensory impairments remain undetected and untreated.

One of the first population-based studies to examine the prevalence of HL in individuals with ID was carried out by Meuwese-Jongejeugd et al. [23]. Their results suggested a significantly higher prevalence of HL in individuals with ID (30.3%) than in the general population (16–17%), with 47.6% of cases undiagnosed prior to the study. The authors further identified Down syndrome and age as pertinent risk factors for HL [23]. The relevance of HL has also been demonstrated in the context of the Special Olympic games, an athletic competition for people with intellectual disabilities [26–28]. An overview of hearing screening measurements performed at the special Olympics in 2007–2017, published in 2022, revealed a high prevalence of HL [28]. Over 100,000 hearing screening measurements were conducted, finding “cerumen impaction [in 40.7%], middle ear problems in 29.5% of those who failed hearing screening, and hearing loss confirmation in 26.9%” [28]. While cerumen impaction was frequent among those who failed the screening (40.7%), such obstructions typically result in only a mild, often reversible HL (approx. 16 dB) [29]. Twenty-three point five percent of participants at the 2006 German Special Olympic games failed hearing screening tests, for which a sensitivity of 100% (95% CI, 98.1% to 100%) and a specificity of 98% (95% CI, 95.1% to 100%) was confirmed [26]. As many as 38% failed hearing screening overall in the 2004 German Special Olympic games [27].

The above-mentioned data underscore the relevance of (1) multiplied disease occurrence in individuals with ID and (2) HL in persons with ID. Without enough sufficiently-specific data, marginalised populations, such as individuals with ID, will continue to be under-represented and subject to insufficient medical care. This study aimed to address the gaps in existing data and care concerning individuals with ID and HL by answering the following questions within our cohort: (1) which comorbidities are most frequently observed in persons with ID and HL; (2) which comorbidities occur more often in this group than in individuals with ID but no HL; (3) whether the severity of both ID and HL influence the quantity of diseases, surgeries, or medication intake. In answering these questions, special consideration is given to factors such as sex and age. Investigating comorbidities in individuals with ID and HL at the intersections of sex and age adds nuance and novelty to the currently limited evidence base.

Methods

Study design and setting

This prospective, age-stratified cohort study, partially population-based in design, was conducted in the geographical area of North Rhine-Westphalia.

Participants

A total of 1,053 participants with ID (mean age 24 years, age range 1–90 years) were included in the outreach group, of whom 390 were female (37%), 662 male (63%), and 1 intersex (< 1%). Additionally, 141 individuals with ID were invited for assessment within clinics as part of a control cohort. However, none of the 12 individuals from the clinical control group who accepted the invitation for hearing screening provided written consent for participation. Therefore, the absence of a control group limits comparative analyses between clinical and outreach settings, and only data from the outreach group is presented in this analysis. The project took place between January 2020 and July 2024, during which time recruitment, screening, data collection, and one-year follow-up took place. The inclusion criteria required that participants had a diagnosed ID and were insured with the project partner, the insurance company AOK-Rhineland. Ethical approval was granted by the ethics committee of the Medical Association of Westphalia-Lippe and the University of Muenster (2020–843-f-S), and complied with the Declaration of Helsinki [30]. The study was registered with the German Clinical Trials Register (DRKS-ID: DRKS00024804). A written project description in plain language was provided to participants with ID in order to ensure that they thoroughly understood and took part in the study voluntarily. The consent form was signed by the participants themselves and/or their legal guardian, depending upon participants’ age, decision-making capacity, and status of guardianship. Caregivers were also released from confidentiality in order to legitimately provide further necessary information relevant to the study. The ability of participants to terminate the study at any time was emphasised, and the work was carried out only on the basis of the ongoing consent of participants and legal guardians throughout.

Participant information was gathered using a questionnaire that had been developed by the study group and was administered to caregivers and, where applicable, to participants typically before the first screening measurements took place. Hearing assessments were performed in the living, educational, and working environments of the participants, creating a setting that was more familiar than a sterile clinical environment. To confirm that the measurement environment was as quiet as possible, the background noise level was measured using a sound level meter to ensure that a noise level of 40 dB(A) was not exceeded. In cases where the sound level meter recorded noise levels of 40 dB(A) or higher, the hearing screening measurements were interrupted and/or relocated to a less noisy environment [31].

The assessments entailed three steps: screening, further diagnostic measurements where necessary, and treatment in cases where HL was identified. The audiometric assessments were performed using the handheld audiometry device Sentiero® (PATH MEDICAL GmbH). The screening process included otoscopy, tympanometry, pure-tone audiometry (air and bone conduction; 0.5–8 kHz), and transiently evoked otoacoustic emissions (TEOAE). For participants unable to undergo conventional audiometry, image-based methods (Multiple-choice Auditory Graphic Interactive Check, MAGIC) or distorted product otoacoustic emissions (DPOAE) were utilised. Inconclusive results were further investigated using brainstem evoked response audiometry (ABR), auditory steady state response (ASSR), DPOAE growth functions, or speech audiometry (Freiburger monosyllabic test or the Mainzer Audiometric Test for Children, MATCH). Following the WHO criteria [32], a hearing impairment was defined as a mean hearing threshold of ≥ 20 dB HL across the frequencies 0.5, 1, 2, and 4 kHz, at both T0 and T1. While isolated hearing losses in the high, mid, or low-frequency ranges were documented, only those meeting the WHO criteria were classified as manifest HL for the purpose of determining prevalence [31, 33]. A detailed description of the entire methodological procedure is published in the study protocol by Schwarze et al. (2021) [34].

Questionnaire

The questionnaire developed by the study group comprised two parts: medical history and assessment of hearing-related quality of life. The part of the study reported here drew upon data from the following subcategories of the first section: general health status, severity of ID as evaluated by the caregivers, ear-specific history, general surgeries, medication, and relevant pre-existing diseases.

The questionnaire section on medical conditions covered a variety of diseases: cardiovascular, neurological, psychiatric, eye, ear, spinal, musculoskeletal, soft tissue, lipo-metabolic; malformations of muscles, skeleton, ears, head, or neck; syndromes associated with HL, such as Alport, Waardenburg, Alström, Usher, Pendred, Cogan-I, and Refsum syndromes; familial HL; and open sections to specify other relevant diseases.

The diseases reported were organised and coded according to the most recent International Classification of Diseases, 11th Revision (ICD-11), by the WHO. The complete list of distinct disease-groups and diseases amounted to 21 overall ICD-11 categories and 290 subcategories.

Manifest HL

Because the program of hearing screening, diagnostics, and intervention was repeated after one year, we were able to distinguish between transient and permanent HL, as well as progressive HL evolving between the first (T0) and second (T1) screening timepoints. Data between T0 and T1 were collected via telephone interviews conducted at least 6 months after T0 to determine the frequency and results of external diagnostic and therapeutic procedures, including hearing aid fitting by our program-affiliated hearing specialists. The reasons for non-utilization of diagnostic or therapeutic measures were recorded using pre-defined categories (e.g., refusal by caregivers/participants, lack of appointments, or missing referral letters) [33, 35]. Manifest HL was defined as permanent (present at T0 and T1) or progressive HL (present at T0, and worsened at T1, or not present at T0 and sensorineural, mixed, or unspecified HL at T1) identified across those two subsequent assessments (algorithm further outlined in supplementary file: Algorithm – Manifest Hearing Loss). Transient or reversible HL was defined as present at either T0 or T1 and was excluded from the presented analysis on manifest HL.

Statistical methods

Relevant items of the pseudonymised questionnaire (diseases, surgeries, medication, previous knowledge of HL) and hearing status were organised and analysed statistically using descriptive statistics (Standard Deviation [SD], mean, Spearman’s Rho) in R (Version 4.4.1, 2024–06–14 ucrt). We describe diseases present in 3% or more of the overall cohort and 5% or more in the subcohorts (with and without HL) in order to achieve sufficient sample size. Associations between HL and individual diseases were evaluated using odds ratios (ORs) with 95% confidence intervals (CIs). Comparisons between groups were conducted using a chi-squared test or Welch’s t-test. All of the tests are two-sided, and a formal significance level of α = 0.05 was used. Binary logistic regressions were performed on data relating to the most common diseases overall (disease prevalence > 3% in the cohort [= 15]) in order to assess the association between each disease and age, sex, HL, and grade of ID [7]. Participants with missing data for a specific covariate (e.g., undetermined grade of ID or unclear hearing status) were excluded from the corresponding analysis. The analyses regarding comorbidities in individuals with ID and HL presented in this manuscript were not the primary endpoint of the overall HörGeist-project for which an initial power calculation and correction for multiple testing was performed. We therefore consider the analyses presented here to be secondary and exploratory. Consequently, none of the reported p-values or confidence intervals were adjusted for multiple testing.

Results

Demographics

Table 1 summarises participants’ demographics, caregiver-rated ID, and hearing status assessed during the study.

Table 1Overview of the cohort stratified by sex, age, with/without manifest HL, degree of ID (as evaluated by caregivers), and degree of manifest HL

Variables With HL n = 417 Without HL n = 554 Unclear n = 82 Overall n = 1,053

Sex

 Male 248 (59%/37%) 353 (64%/53%) 61 (74%/9.2%) 662 (63%/100%)

 Female 169 (41%/43%) 200 (36%/51%) 21 (26%/5.4%) 390 (37%/100%)

 Intersex 0 (0%/0%) 1 (0.2%/100%) 0 (0%/0%) 1 (< 0.1%/100%)

Age*

 0–5 52 (12%/23%) 147 (27%/64%) 32 (39%/14%) 231 (22%/100%)

 6–11 64 (15%/26%) 159 (29%/64%) 26 (32%/10%) 249 (24%/100%)

 12–17 38 (9.1%/24%) 110 (20%/71%) 8 (9.8%/5.1%) 156 (15%/100%)

 18–34 28 (6.7%/26%) 73 (13%/68%) 7 (8.5%/6.5%) 108 (10%/100%)

 35–49 57 (14%/62%) 30 (5.4%/33%) 5 (6.1%/5.4%) 92 (8.7%/100%)

 50–69 144 (35%/80%) 34 (6.1%/19%) 3 (3.7%/1.7%) 181 (17%/100%)

  ≥70 34 (8.2%/94%) 1 (0.2%/2.8%) 1 (1.2%/2.8%) 36 (3.4%/100%)

Degree of ID

 Mild 75 (18%/27%) 178 (32%/65%) 20 (24%/7.3%) 273 (26%/100%)

 Moderate 184 (44%/44%) 209 (38%/49%) 35 (43%/8.2%) 428 (41%/100%)

 Severe 129 (31%/45%) 135 (24%/47%) 23 (28%/8.0%) 287 (27%/100%)

 (missing**) 29 (7.0%/45%) 32 (5.8%/49%) 4 (4.9%/6.2%) 65 (6.2%/100%)

Degree of HL

 Mild 156 (37%) - - 156 (15%)

 Moderate 87 (21%) - - 87 (8.3%)

 Moderately severe 54 (13%) - - 54 (5.1%)

 Severe 22 (5.3%) - - 22 (2.1%)

 Profound 5 (1.2%) - - 5 (0.5%)

 Complete 9 (2.2%) - - 9 (0.9%)

 (missing**) 25 (6.0%/23%) - 82 (100%/77%) 107 (10%/100%)

Unilateral HL 59 (14%/9.6%) - - 59 (5.6%/100%)

Percentages are reported first as column percentages (within the “with HL”/“without HL” subgroups) and secondly (in italics) relative to the entire cohort (row percentages). *Narrower age intervals stated in order to be able to distinguish life-cycle phases, such as puberty and menopause  **Participants with missing data for a specific covariate (e.g., undetermined grade of ID or unclear hearing status) were excluded from the corresponding analysis

Manifest HL

Our findings represent associations observed within our cohort and should be considered hypothesis-generating. Therefore, the results do not imply causality. Among the 1,053 participants, 443 (42%) had no HL, 417 (40%) a manifest HL, 111 (11%) a transient HL, and in 82 (8%) the hearing status remained unclear. For the subsequent analysis, participants with transient HL were categorised as having no manifest HL. Among participants with manifest HL, the type of HL was conductive in 22% of cases, sensorineural in 42%, mixed in 12%, and remained unspecified in 25%. Our data exhibited an increase in HL prevalence, as expected, with age (Table 1) from 23% (0–5 yrs) to 94% (≥ 70 yrs). Of the 417 individuals with manifest HL, approximately 1/3 had mild HL (n = 156, 37%), 21% moderate (n = 87), 13% moderately-severe HL (n = 54), 5.3% (n = 22) severe, 1.2% (n = 5) profound, and 2.2% (n = 9) complete HL. For 25 participants (6%), HL was identified, but the exact degree of severity could not be determined due to participant restlessness or insufficient data points. Fourteen percent (n = 59) showed unilateral HL. Caregivers evaluated the degree of ID as mild in 18% (n = 75), moderate in 44% (n = 184), and severe in 31% (n = 129), with 7% (n = 29) missing due to incomplete records. Among participants with manifest HL, only 2.4% had persistent non-removable cerumen obturans at both the T0 and T1 screening assessments. The algorithm defining manifest HL excluded those with transient HL, suggesting that transient conditions were unlikely to have substantially influenced the prevalence of manifest HL.

The ten most common ICD-11 disease categories

The ten most common ICD-11 disease categories (prevalence > 5% in the overall cohort) reported in the overall study cohort (with ID, with and without HL) were: diseases of the endocrine, nutritional, or metabolic system (n = 268, 25.5%); developmental anomalies (n = 263, 25%); nervous system disorders (n = 244, 23.2%); mental, behavioural, or neurodevelopmental disorders (n = 243, 23.1%); visual system disorders (n = 187, 17.8%); circulatory system disorders (n = 172, 16.3%); musculoskeletal system or connective tissue disorders (n = 99, 9.4%); symptoms, signs, or clinical findings not elsewhere classified (n = 84, 8%) (e.g., auditory hallucinations, tinnitus); ear or mastoid process disorders (n = 57, 5.4%); and factors influencing health status or contact with health services (n = 57, 5.4%) (e.g., ear or visual conditions documented in the medical history).

The most common disease categories (ICD-11) identified among participants with and without HL showed the same categories but differed in prevalence. The comparison of all ICD-11 disease categories detected in the overall study cohort, contrasting those with and without HL, is illustrated in Fig. 1, highlighting sex differences within each disease category.

Most common disease subcategories

The most common subcategories identified in the overall cohort (disease prevalence > 3% in the cohort, 15 subcategories) were: visual system diseases; epilepsy; obesity; ASD (autism spectrum disorder); hypertension; trisomy 21; neuromuscular disorders; nutritional disorders; skeletal anomalies; spinal conditions; mental, behavioural, or neurodevelopmental disorders; myocardial diseases; family history of eye/ear conditions; diabetes; and hypothyroidism. In the cohort without HL (disease prevalence > 5% in the subcohort, 9 subcategories), the most common subcategories were ASD; visual system diseases; epilepsy; obesity; nutritional disorders; neuromuscular disorders; skeletal anomalies; family history of eye/ear disorders; and myocardial diseases.

In the cohort with HL (disease prevalence > 5% in the subcohort, 14 subcategories), the most common subcategories were visual system diseases; hypertension; obesity; trisomy 21; epilepsy; neuromuscular disorders; skeletal anomalies; mental, behavioural, or neurodevelopmental disorders; spinal conditions; nutritional disorders; diabetes; myocardial diseases; hypothyroidism; and family history of eye/ear disorders.

Comparison of common disease subcategories in participants with and without HL

Nearly all comorbidities found in participants with HL occurred more frequently in those with than without HL (13 out of 14), eight of which showed an OR and 95% CI > 1 (Fig. 2).

Visual impairment was found in 22.8% of participants with ID and HL vs. 13.7% without HL (OR 1.86, 95% CI: 1.3, 2.6), suggesting a one- to twofold higher occurrence in participants with HL. Hypertension occurred in 18% with HL vs. 4.9% without (OR 4.28, 95% CI: 2.7, 6.8), suggesting a fourfold increase. Trisomy 21 was detected in 15.8% with HL and 4.7% without (OR 3.82, 95% CI: 2.3, 6.2), thus occurring three to four times more often.

Obesity, among the four most common diseases in both groups, was observed nearly twice as often in participants with HL (17%) as in those without (9.6%) (OR 1.94, 95% CI: 1.3, 2.9). Mental, behavioural, or neurodevelopmental disorders were observed in 10.1% with HL vs. 2.9% without (OR 3.77, 95% CI: 2.0, 6.8); spinal conditions in 9.8% with HL vs. 4.5% without (OR 2.31, 95% CI: 1.3, 3.9); diabetes in 8.4% with HL vs. 1.4% without (OR 6.25, 95% CI: 2.8, 13.6); and hypothyroidism in 7.2% vs. 1.8% without (OR 4.22, 95% CI: 2.0, 8.8). All of these diseases except spinal conditions were more commonly observed in female than in male participants within the HL subgroup (Fig. 2), especially relevant in regard to trisomy 21 (p = 0.034, Chi-squared test).

Similar proportions of participants with HL (12.9%) and without HL (12.3%) reported epilepsy, underscoring its importance in both groups (OR 1.06, 95% CI: 0.7, 1.6). ASD was found less often in participants with HL than without (OR 0.28, 95% CI: 0.1, 0.5).

Trisomy 21

Trisomy 21 is a known risk factor for HL [23]. We therefore analysed co-occurring diseases and HL in this group separately. Among 98 participants with trisomy 21, 51% were male, 49% female, mean age was 25 yrs (SD 22). The most common comorbidities (> 5% of the trisomy 21 subgroup) were diseases of the visual system and visual impairment (n = 23, 23.5%); obesity (n = 21, 21.4%); hypothyroidism; myocardial diseases (each n = 12, 12.2%); nutritional disorders (n = 8, 8.2%); neuromuscular disorders (n = 7, 7.1%); hypertension (n = 7, 7.1%); middle ear or mastoid disorders (n = 6, 6.1%); skeletal anomalies (n = 6, 6.1%); dyslipidaemias (n = 5, 5.1%); and spinal conditions (n = 5, 5.1%).

Sixty-seven percent (n = 66) of participants with trisomy 21 within our study were diagnosed with manifest HL but only 27% (n = 26) of those without. The most common type of HL found within this group was conductive (24%), followed by sensorineural (18%), and mixed HL (10%). In 18%, the type of HL remained unspecified.

The extent of medication intake, (multi-)morbidity, and surgery

Medication intake in participants with and without HL

The mean number of medications taken by participants with HL was 2.73 (SD 3.04) vs. 0.84 (SD 1.56) in those without HL, and thus higher in the subgroup with HL (p < 0.001, Welch test). The mean number of surgeries did not differ substantially. A small association was observed between the grade of HL and medication intake overall (Spearman’s Rho (95%-CI) 0.162 (0.06, 0.262)) and especially in females (Spearman’s Rho (95%-CI) 0.207 (0.044, 0.359)).

(Multi-)morbidity in participants with and without HL

The mean number of additional diseases was 2.75 (SD 2.35) in participants with HL vs. 1.65 (SD 1.87) without, and therefore higher in the subgroup with HL (p < 0.001, Welch test). Multimorbidity (two or more chronic diseases [36]) was observed in 49.8% (n = 524) of the cohort, 21 percentage points higher in those with ID and HL (63%) than in those without (42%) (p < 0.001, Chi-squared test). The highest number of diseases in a single participant was 14 (Fig. 3). Among those with ID and HL, 16% had no additional diseases, 21% had one, and 63% had two or more, vs. 35% (none), 23% (one), and 42% (two or more) without HL. A small association was observed between the number of comorbidities and the grade of HL (Spearman’s Rho (95%-CI) 0.192 (−0.036, 0.34)), as well as the number of comorbidities and degree of ID (Spearman’s Rho (95%-CI) 0.175 (0.019,0.322)) in females.

Previously undetected manifest HL

Information regarding previous knowledge of HL was available in 1,003 participants. Eighty-five percent (n = 856) of these participants stated that HL was not previously known. However, 40% (n = 400) were diagnosed with a manifest HL, and 29% (n = 290) were found to have manifest, previously overlooked HL. Therefore, of all participants with manifest HL identified in this study, 72.5% had not been previously diagnosed. This group had a slight female preponderance (p = 0.41, Chi-squared test): 26% of male participants with previously undetected HL vs. 30% female participants.

Comorbidities in context: associations with sex, HL, degree of ID, and age

A logistic regression analysis was performed in order to contextualise the overall most common disease subcategories (disease prevalence > 3% in overall study cohort, [15 subcategories]) portraying each disease subcategory’s association with sex, HL, degree of ID, and age group, while controlling for the other variables (Table 2).Table 2Logistic regression of disease subcategories and their association with sex, HL, degree of ID, and age

Sex Degree of ID* HL Age group

Disease Ref: Male Mild Moderate Severe Ref: without 0–17 18–49 50 + 

Diseases of the visual system and visual impairment ᵃ 1.36 (0.95,1.93) Ref 1.16 (0.75,1.81) 1.23 (0.76,2.01) 1.58 (1.06,2.34) Ref 1.32 (0.83,2.06) 1.6 (1,2.54)

Epilepsy or seizures, unspecified ᵇ 0.97 (0.64,1.45) Ref 1.54 (0.89,2.78) 3.36 (1.94,6.03) 1.01 (0.65,1.56) Ref 1.04 (0.61,1.71) 0.97 (0.54,1.69)

Obesity ᶜ 1.49 (0.99,2.24) Ref 0.89 (0.54,1.48) 1.23 (0.71,2.15) 0.95 (0.59,1.51) Ref 3.83 (2.25,6.54) 6.11 (3.52,10.78)

Autism spectrum disorder (ASD) ᵈ 0.5 (0.29,0.82) Ref 1.85 (1.03,3.46) 2.55 (1.4,4.8) 0.42 (0.24,0.73) Ref 0.23 (0.09,0.47) 0.09 (0.01,0.31)

Hypertension ᵉ 1.01 (0.61,1.65) Ref 1 (0.56,1.8) 0.85 (0.41,1.75) 1.02 (0.56,1.87) Ref 6.55 (2.69,17.54) 37.84 (16.72,98.43)

Complete trisomy 21 ᶠ 2.18 (1.37,3.5) Ref 1.82 (0.96,3.67) 1.82 (0.91,3.79) 4.73 (2.78,8.25) Ref 0.92 (0.5,1.65) 0.49 (0.25,0.9)

Diseases of neuromuscular junction or muscle ᵍ 1.07 (0.66,1.72) Ref 2 (0.98,4.4) 4.18 (2.1,9.1) 1.67 (1.01,2.77) Ref 0.34 (0.15,0.7) 0.56 (0.28,1.06)

Nutritional disorders ʰ 1.6 (1,2.55) Ref 1.49 (0.81,2.83) 1.7 (0.89,3.33) 1.13 (0.66,1.89) Ref 0.66 (0.33,1.23) 0.58 (0.28,1.14)

Structural developmental anomalies of the skeleton ⁱ 1.33 (0.83,2.11) Ref 1.18 (0.65,2.23) 1.87 (1.01,3.59) 1.36 (0.81,2.27) Ref 1.12 (0.6,2.02) 1.19 (0.63,2.21)

Conditions associated with the spine ʲ 1.22 (0.71,2.07) Ref 1.68 (0.8,3.88) 3.02 (1.41,7.07) 1.83 (1.02,3.34) Ref 1.93 (0.98,3.7) 1.79 (0.89,3.6)

Mental, behavioural or neurodevelopmental disorders ᵏ 1.62 (0.91,2.91) Ref 1.09 (0.53,2.34) 1.47 (0.65,3.41) 1.6 (0.81,3.3) Ref 5.49 (2.3,14.05) 9.3 (4,23.92)

Diseases of the myocardium or cardiac chambers and cardiomyopathyˡ 1.91 (1.12,3.3) Ref 1.52 (0.73,3.41) 2.78 (1.31,6.29) 1.03 (0.56,1.91) Ref 0.73 (0.31,1.58) 1.7 (0.84,3.43)

Family history of eye or ear disorders ᵐ 0.66 (0.34,1.23) Ref 0.95 (0.47,1.98) 0.89 (0.41,1.93) 1.46 (0.76,2.76) Ref 0.26 (0.08,0.66) 0.33 (0.12,0.81)

Diabetes ⁿ 1.26 (0.64,2.46) Ref 0.48 (0.23,1.02) 0.45 (0.16,1.16) 2.21 (0.94,5.69) Ref 6.18 (1.67,29.24) 21.99 (7.02,98)

Hypothyroidism ᵒ 2.3 (1.2,4.53) Ref 1.12 (0.51,2.67) 1.04 (0.4,2.75) 2.95 (1.35,6.86) Ref 3.16 (1.33,7.73) 2.63 (1.1,6.6)

Logistic regression of the most common disease subcategories for the whole sample (disease prevalence > 3% of the study cohort, [= 15]) in individuals with ID and HL and their association with sex, HL, degree of ID, and age group. Odds ratios are indicated in parentheses. OR and 95% CI > 1 is highlighted in bold. Reversed associations are highlighted in bold and italic. ICD-11 codes corresponding to each subcategory are listed below the table, as indicated by the superscript letters (a–o)

*As evaluated by caregivers; ICD-11 codes for each disease subcategory: ᵃ9E1Z, 9D9Z, 9D00.0, 9C8Z, 9B10, 9D90, 9D00.1, 9D00.2, 9C6Z, 9C84.Z, 9B11.0, 9B71.0Z, 9C40.BZ, 9C82.4; ᵇ8A6Z; ᶜ5B81.Z; ᵈ6A02.Z; ᵉBA00.Y, BA00.Z; ᶠLD40.0; ᵍ8D0Z; ʰ 5C3Z; ⁱ LB9Z; ʲ FB1Z; ᵏ6E8Z; ˡBC43.0, BC43.1, BC4Z; ᵐQC66; ⁿ5A14, 5A11; ᵒ5A00.Z

Sex, degree of ID, HL, age

Sex: Trisomy 21, nutritional disorders, myocardial diseases, and hypothyroidism showed a female preponderance, while ASD exhibited a male preponderance. Degree of ID: Epilepsy, ASD, neuromuscular diseases, skeletal anomalies, spinal conditions, and myocardial diseases increased with higher degrees of ID. HL: HL was associated with visual impairment, trisomy 21, neuromuscular disorders, spinal conditions, and hypothyroidism, while ASD was inversely associated with HL. Age: Visual impairment, hypertension, obesity, mental, behavioural, or neurodevelopmental disorders, and diabetes increased with age. Hypothyroidism showed the highest prevalence in the middle-aged group. ASD, trisomy 21, and family history of eye or ear disorders exhibited a reversed age association.

Discussion

We assessed the medical history of individuals with ID with and without manifest HL in order to evaluate (1) which comorbidities typically occur in people with ID and HL, (2) which of them occur in higher proportions in those with and without HL, and (3) whether severity of ID or HL influenced quantity of diseases, surgeries, or medication intake. To our knowledge, no existing literature compares disease occurrence in individuals with ID with and without HL. Our findings, which addressed age and sex, and systematised the data according to ICD-11, are a timely step toward better understanding this overlooked population within individuals with ID. This is especially important given that existing literature points to higher disease occurrence, morbidity, mortality, and undetected HL in individuals with ID in general. Examining and comparing these intersections adds knowledge about this group and their distinct needs.

Our findings suggest a higher prevalence of disease in individuals with both ID and HL than in those without HL for the majority of diseases assessed, thereby complementing and extending the existing literature reporting higher morbidity in individuals with ID [3–14] or HL [37]. Eight subcategories in the HL subcohort showed a higher prevalence with OR and 95% CI > 1: visual impairment; hypertension; trisomy 21; obesity; mental, behavioural, or neurodevelopmental disorders; spinal conditions; diabetes; and hypothyroidism. Among these eight, logistic regression highlighted the following: (1) associations between HL and visual impairment, trisomy 21, spinal conditions, hypothyroidism; (2) hypertension, obesity, and diabetes as being predominantly associated with increasing age; and (3) female sex correlated with trisomy 21 and hypothyroidism.

The overall high prevalence of visual impairment in our cohort stands in stark contrast to the prevalence of visual impairment reported for the adult general population in Germany (0.37%) [38]. Visual impairment was the most common comorbidity in both the overall cohort and the subcohort with ID and HL, aligning with previous research in individuals with ID [7]. This highlights the importance of multi-sensory impairment in individuals with ID. Sensory impairments, especially when co-occurring with other diseases, can be overlooked in individuals with ID – a phenomenon described as "diagnostic overshadowing" [39]. We detected visual system diseases in 22.8% of the HL subcohort, which supports the 21.4% prevalence of combined visual impairment and HL found in an Austrian study [39, 40]. Contrary to existing findings [41–43], our data did not replicate an association between visual impairment and higher degrees of ID, though it shows an increase with age [43]. Our observed association of the intersection of age, HL, and visual impairment mirrors the established evidence that sensory organs are more severely affected by aging than other types of organs [39]. The common co-occurrence of these sensory deficits likely also reflects shared pathophysiological pathways or frequent genetic aetiologies, rather than merely being a coincidental accumulation of age- or ID-related morbidity. A well-characterised example is Usher syndrome, in which mutations in genes (e.g. MYO7A) disrupt structures essential to both mechanotransduction in cochlear hair cells and function of photoreceptor/retinal pigment epithelium. As a result, individuals with Usher syndrome can exhibit combined vision impairment and HL [44].

Trisomy 21 occurred in 9.35% of our overall cohort, substantially higher compared to the general population estimates in Germany of 0.6% [45]. Trisomy 21, the most common known cause of ID [46], is an established risk factor for HL [23]. Our data showed a three- to fourfold higher occurrence of trisomy 21 in individuals with HL than in those without, and a female preponderance. Trisomy 21 showed associations with HL and high rates of visual diseases, as well as cardiovascular and metabolic co-occurring diseases (obesity, hypothyroidism, myocardial diseases, nutritional disorders, hypertension, dyslipidaemia). A 67% rate of manifest HL indicates pronounced (multi-)sensory impairment and aligns with existing findings on high rates of obesity, hypertension, and visual and hearing impairment in individuals with ID and trisomy 21 [7]. The high prevalence of HL in trisomy 21 has traditionally been attributed to craniofacial anatomical features predisposing to otitis media with effusion (OME), such as a small nasopharynx, narrow palate and (oro-)pharynx, stenotic external ear canal, dysplasia of the inner ear, flat nasal bridge, and malformation of the eustachian tube [47]. However, more recent work has also identified specific genetic drivers (e.g. DYRK1A) that promote middle-ear mucosal inflammation and effusion [48].

Hypothyroidism has been associated with HL and female sex in the general population [49]. We also observed this association in our analysis for the population with ID, suggesting links between hypothyroidism, HL, and female sex. The association between hypothyroidism and HL is pathophysiologically plausible, given the essential role of thyroid hormones in the development and function of the cochlea, including the differentiation and maturation of sensory hair cells (electromotility and potassium ion channel development), expression of ion channels, and synaptic maturation [50–52]. Thyroid hormone deficiency can directly impair these processes, for example by inducing β-tectorin protein deficiency, leading to structural abnormalities of the tectorial membrane and thereby predisposing to HL [52, 53].

Epilepsy occurred in similar proportions in both subcohorts (with HL 12.9%, without HL 12.3%) as one of the top 5 diseases, confirming its known relevance in individuals with ID [8], especially in contrast to prevalence estimates reported in the adult general population in Germany (0.95 to 1.09%) [54].

ASD was the most common disease subcategory in our cohort with ID and no HL (14.4%), with a clear male preponderance, aligning with previous observations [55, 56]. The occurrence of ASD within our cohort (10.4% overall, 14.4% without HL, 4.6% with HL) is notably higher than global estimates for the general population (0.65%) [57]. Studies on HL prevalence in ASD are scarce [39]; in our cohort, HL was less associated with ASD in both descriptive and regression analyses than in the sub-cohort without HL. Theories regarding the biological and sociological reasons underlying sex differences in ASD are subjects of ongoing discussion, and more research integrating critical approaches is necessary in order to illuminate this area [58].

A small association was observed between the number of comorbidities and greater severity of HL and ID, selectively in females, which supports existing evidence linking multimorbidity and female sex in both general [59] and ID populations [5]. This suggests an intersectional effect – overlapping female sex, ID, HL, and further diseases – and warrants further attention. Severity of HL also suggested an association between increasing degree of HL with medication intake in females.

Multimorbidity (more than two chronic diseases [36, 60]) was observed in nearly half of the cohort and was 21% higher in those with ID and HL (63%) than in without (42%). Existing evidence has found a similar rate of multimorbidity in individuals with ID (40% in Cooper et al. 2015 [5]), whereas multimorbidity in ID and HL has not been reported to date.

Multimorbidity and polypharmacy are strong predictors of mortality in older individuals with ID [61]. This underlines the need for early disease assessment and management in order to prevent progression and complications. Multimorbidity is complex, aetiologically influenced by age and sociocultural factors [60], and requires sustainable, cross-sectoral care that accounts for multifaceted lived realities.

40% of our cohort had manifest HL, 72.5% of which was undetected prior to the study. Dutch [23], German [62], and Austrian [40] studies reported high HL prevalence in individuals with ID (35.8%, 37.8%, 47%) and frequent lack of prior detection (47.6%, 28%, 72.8%). Despite differing scopes, the key implication of these studies is the need for systematic HL assessment in individuals with ID in order to detect and treat HL – and thereby other possible comorbidities – as early as possible.

Limitations

Despite careful study design in cooperation with individuals with ID, caregivers, and their environment, a truly participatory approach with more active and equal roles would have added value. Medical history was collected orally and in writing, but would ideally have been complemented by further specific physical examinations and diagnostics [7], which were unfortunately not possible because of limited resources. Furthermore, the absence of a control group limits comparative analyses between clinical and outreach settings. The fact that the clinical control group did not participate ultimately underscores one of the core outcomes of our project overall: the critical necessity of outreach screening, as people with ID remain systematically underserved in traditional clinical settings [26, 63]. Transient HL was not included in the present analysis, but would warrant further investigation because of the risk of developing into manifest HL over time. Nevertheless, for our present analysis, the exclusion of participants with transient HL from the final analysis is unlikely to have strongly influenced the overall findings. Data from T1 showed that the prevalence of newly occurring HL at T1 (6.5%) was nearly balanced by the prevalence of HL that had resolved since T0 (7.0%). This suggests that the bidirectional fluctuations in hearing status largely offset each other. While this approach may potentially overlook individuals with highly recurrent conditions, such as repeated otitis media with effusion, the longitudinal screening design of the program is specifically intended to identify such patterns over time. Despite adjustment for age, sex, and severity of ID, residual confounding due to unmeasured factors such as care setting, socioeconomic status, and utilisation of healthcare cannot be ruled out. As all p-values were interpreted in an exploratory manner without adjustment for multiple testing, findings should be considered hypothesis-generating rather than confirmatory or causal, and should therefore be interpreted with caution. This cohort was recruited within a specific insurance context and geographic region (North Rhine-Westphalia), which may limit the generalisability of findings to broader populations, including those without statutory health insurance or in other healthcare systems. These limitations suggest avenues for potential future research and innovation.

The extent of co-occurring diseases, multimorbidity, and multiplied medication intake in participants with ID (and HL) emphasises the need for targeted attention and multidisciplinary, cross-sectoral healthcare. Each newly-diagnosed disease should serve as an indicator for further diagnostics in order to facilitate prevention and early intervention. General practitioners have the distinct responsibility, as long-term primary physicians, to integrate medical history and disease management with early referral to specialist care. This could be facilitated by the implementation of a cross-sectoral digital patient record within Germany in order to prevent information loss and ensure continuous, coordinated care. Increased awareness of the associations between ID, HL, and various distinct comorbidities should encourage general practitioners and specialists – especially paediatricians, ear, nose and throat (ENT) specialists, and specialists in phoniatrics and paediatric audiology – to pay particular attention to these interconnections. This would include, for example, considering screening for HL and other comorbidities for all individuals with ID. Clinical practice guidelines could serve as tools for fostering awareness and facilitating the comprehensive uptake of hearing screening within clinical care – especially for underserved populations [64].

Recent efforts to create and critically evaluate targeted diagnostics and care for diverse, underserved populations reflect a much-needed patient-centred approach [65–70]. For example, behavioural similarities between individuals with ASD, ID, and sensory impairment can complicate their differentiation at assessment. Diagnostic tools to aid this work have been proposed [68]. Sun et al. highlight the need for specific considerations regarding intervention as well as systematic seizure management in individuals with ID and epilepsy by developing a framework for targeted care which may serve as a good practice example [69]. One way to incentivise a multidisciplinary approach and foster structural change may involve resource allocation, e.g. monetary compensation.

Ableism (discrimination and devaluation on account of disabilities [71]) is societally-embedded at the structural, institutional, and individual level, including within healthcare. Individuals with ID and HL, often subsumed under the umbrella of so-called “disabilities”, face barriers and discrimination. As marginalised populations, they require heightened sensitivity, awareness, multidisciplinary care, and representative, disaggregated data that accurately capture their reality.

Conclusion

Our findings identified (1) visual system diseases, epilepsy, and obesity as the most common comorbidities, with a high prevalence across the entire cohort. Concerning (2) the difference in prevalence of comorbidities between those with and without HL, our findings suggest increased comorbidity, multimorbidity, and higher intake of medication in individuals with HL than those without. Nearly all comorbidities observed in participants with HL (prevalence > 5% [= 14]) were more frequent in participants with HL vs. without (13/14), eight showing OR and 95% CI > 1: visual impairment; hypertension; trisomy 21; obesity; mental, behavioural, or neurodevelopmental disorders; spinal conditions; diabetes; hypothyroidism. Regarding (3) the influence of the degree of ID or HL, we found that higher degrees of ID are associated with an increased number of comorbidities, particularly epilepsy, ASD, neuromuscular, skeletal, spinal, and myocardial diseases. Beyond these associations, our results indicate that individuals with ID also seem to face compounded healthcare barriers – including data gaps, ableism, communication barriers, and limited access to care. Heightened awareness of the complex interplay between ID, HL, and their distinct comorbidities must translate into clinical practice. This entails general practitioners and specialists – particularly paediatricians, ENT-physicians, and specialists in phoniatrics and paediatric audiology – being especially attuned to these interconnections. Progress towards more equitable healthcare requires systematic implementation of differentiated, inclusive data generation, and distinct strategies in order to promote targeted, inclusive, multidisciplinary, person-centred, cross-sectoral care.

Supplementary Information

References

1.Nair R Chen M Dutt AS Hagopian L Singh A Du M Significant regional inequalities in the prevalence of intellectual disability and trends from 1990 to 2019: a systematic analysis of GBD 2019 Epidemiol Psychiatr Sci 2022 31 e91 10.1017/S2045796022000701 36539341 PMC9805697 Nair R, Chen M, Dutt AS, Hagopian L, Singh A, Du M. Significant regional inequalities in the prevalence of intellectual disability and trends from 1990 to 2019: a systematic analysis of GBD 2019. Epidemiol Psychiatr Sci. 2022;31:e91. 10.1017/S2045796022000701 .PMC9805697 36539341

2.Bundesamt S Statistik der schwerbehinderten Menschen 2022 WiesbadenStatistisches Bundesamt DeutschlandBundesamt S. Statistik der schwerbehinderten Menschen. Wiesbaden: Statistisches Bundesamt Deutschland; 2022.

3.Sappok T Diefenbacher A Winterholler M The Medical Care of People With Intellectual Disability Dtsch Arztebl Int 2019 116 809 816 10.3238/arztebl.2019.0809 31888794 PMC6947689 Sappok T, Diefenbacher A, Winterholler M. The Medical Care of People With Intellectual Disability. Dtsch Arztebl Int. 2019;116:809–16. 10.3238/arztebl.2019.0809 .PMC6947689 31888794

4.Carey IM Shah SM Hosking FJ DeWilde S Harris T Beighton C Cook DG Health characteristics and consultation patterns of people with intellectual disability: a cross-sectional database study in English general practice Br J Gen Pract 2016 66 e264 e270 10.3399/bjgp16X684301 26906630 PMC4809710 Carey IM, Shah SM, Hosking FJ, DeWilde S, Harris T, Beighton C, et al. Health characteristics and consultation patterns of people with intellectual disability: a cross-sectional database study in English general practice. Br J Gen Pract. 2016;66:e264–70. 10.3399/bjgp16X684301 .PMC4809710 26906630

5.Cooper S-A McLean G Guthrie B McConnachie A Mercer S Sullivan F Morrison J Multiple physical and mental health comorbidity in adults with intellectual disabilities: population-based cross-sectional analysis BMC Fam Pract 2015 16 110 10.1186/s12875-015-0329-3 26310664 PMC4551707 Cooper S-A, McLean G, Guthrie B, McConnachie A, Mercer S, Sullivan F, et al. Multiple physical and mental health comorbidity in adults with intellectual disabilities: population-based cross-sectional analysis. BMC Fam Pract. 2015;16:110. 10.1186/s12875-015-0329-3 .PMC4551707 26310664

6.Emerson E Hatton C Baines S Robertson J The physical health of British adults with intellectual disability: cross sectional study Int J Equity Health 2016 15 11 10.1186/s12939-016-0296-x 26791808 PMC4719222 Emerson E, Hatton C, Baines S, Robertson J. The physical health of British adults with intellectual disability: cross sectional study. Int J Equity Health. 2016;15:11. 10.1186/s12939-016-0296-x .PMC4719222 26791808

7.Kinnear D, Morrison J, Allan L, Henderson A, Smiley E, Cooper S-A. Prevalence of physical conditions and multimorbidity in a cohort of adults with intellectual disabilities with and without Down syndrome: cross-sectional study. BMJ Open. 2018. 10.1136/bmjopen-2017-018292 .PMC5829598 29431619

8.Liao P Vajdic C Trollor J Reppermund S Prevalence and incidence of physical health conditions in people with intellectual disability - a systematic review PLoS One 2021 16 e0256294 10.1371/journal.pone.0256294 34428249 PMC8384165 Liao P, Vajdic C, Trollor J, Reppermund S. Prevalence and incidence of physical health conditions in people with intellectual disability - a systematic review. PLoS One. 2021;16:e0256294. 10.1371/journal.pone.0256294 .PMC8384165 34428249

9.McMahon M Hatton C A comparison of the prevalence of health problems among adults with and without intellectual disability: A total administrative population study J Appl Res Intellect Disabil 2021 34 316 325 10.1111/jar.12785 32734651 McMahon M, Hatton C. A comparison of the prevalence of health problems among adults with and without intellectual disability: A total administrative population study. J Appl Res Intellect Disabil. 2021;34:316–25. 10.1111/jar.12785 .32734651

10.Morin D Mérineau-Côté J Ouellette-Kuntz H Tassé MJ Kerr M A comparison of the prevalence of chronic disease among people with and without intellectual disability Am J Intellect Dev Disabil 2012 117 455 463 10.1352/1944-7558-117.6.455 23167485 Morin D, Mérineau-Côté J, Ouellette-Kuntz H, Tassé MJ, Kerr M. A comparison of the prevalence of chronic disease among people with and without intellectual disability. Am J Intellect Dev Disabil. 2012;117:455–63. 10.1352/1944-7558-117.6.455 .23167485

11.van Eeghen AM Huisman SA van Goethem G Boot E Somatic comorbidity in children and adults with intellectual disability and mental health problems [Somatische comorbiditeit bij kinderen en volwassenen met een verstandelijke beperking en een psychiatrische aandoening] Tijdschr Psychiatr 2019 61 773 778 31907887 van Eeghen AM, Huisman SA, van Goethem G, Boot E. Somatic comorbidity in children and adults with intellectual disability and mental health problems [Somatische comorbiditeit bij kinderen en volwassenen met een verstandelijke beperking en een psychiatrische aandoening]. Tijdschr Psychiatr. 2019;61:773–8.31907887

12.van Schrojenstein Lantman-de Valk HM, Metsemakers JF, Haveman MJ, Crebolder HF. Health problems in people with intellectual disability in general practice: a comparative study. Fam Pract. 2000;17:405-7. 10.1093/fampra/17.5.405 .11021900

13.van Timmeren EA, Waninge A, van Schrojenstein Lantman-de Valk HM, van der Putten, AAJ, van der Schans, CP. Patterns of multimorbidity in people with severe or profound intellectual and motor disabilities. Res Dev Disabil. 2017;67:28-33. 10.1016/j.ridd.2017.05.002 .28622657

14.Sappok T, Sinzig J, Lehmkuhl G, Diefenbacher ABM. Kapitel 24: Intelligenzminderung Psychische Erkrankungen, Klinik und Therapie. München: Elsevier Urban & Fischer; 2018. (6).

15.McCallion P McCarron M Deaths of people with intellectual disabilities in the UK Lancet 2014 383 853 855 10.1016/S0140-6736(13)62190-X 24332308 McCallion P, McCarron M. Deaths of people with intellectual disabilities in the UK. Lancet. 2014;383:853–5. 10.1016/S0140-6736(13)62190-X .24332308

16.Reppermund S Srasuebkul P Dean K Trollor JN Factors associated with death in people with intellectual disability J Appl Res Intellect Disabil 2020 33 420 429 10.1111/jar.12684 31786826 Reppermund S, Srasuebkul P, Dean K, Trollor JN. Factors associated with death in people with intellectual disability. J Appl Res Intellect Disabil. 2020;33:420–9. 10.1111/jar.12684 .31786826

17.O’Leary L Cooper S-A Hughes-McCormack L Early death and causes of death of people with intellectual disabilities: A systematic review J Appl Res Intellect Disabil 2018 31 325 342 10.1111/jar.12417 28984406 O’Leary L, Cooper S-A, Hughes-McCormack L. Early death and causes of death of people with intellectual disabilities: A systematic review. J Appl Res Intellect Disabil. 2018;31:325–42. 10.1111/jar.12417 .28984406

18.Ng N Flygare Wallén E Ahlström G Mortality patterns and risk among older men and women with intellectual disability: a Swedish national retrospective cohort study BMC Geriatr 2017 17 269 10.1186/s12877-017-0665-3 29166873 PMC5700486 Ng N, Flygare Wallén E, Ahlström G. Mortality patterns and risk among older men and women with intellectual disability: a Swedish national retrospective cohort study. BMC Geriatr. 2017;17:269. 10.1186/s12877-017-0665-3 .PMC5700486 29166873

19.Thygesen LC Klitgaard MB Sabers A Kjellberg J Søndergaard J Sørensen J Potentially avoidable mortality among adults with intellectual disability Eur J Public Health 2024 34 1225 1231 10.1093/eurpub/ckae118 39107978 PMC11631387 Thygesen LC, Klitgaard MB, Sabers A, Kjellberg J, Søndergaard J, Sørensen J, et al. Potentially avoidable mortality among adults with intellectual disability. Eur J Public Health. 2024;34:1225–31. 10.1093/eurpub/ckae118 .PMC11631387 39107978

20.Heslop P Blair PS Fleming P Hoghton M Marriott A Russ L The confidential inquiry into premature deaths of people with intellectual disabilities in the UK: a population-based study Lancet 2014 383 889 895 10.1016/S0140-6736(13)62026-7 24332307 Heslop P, Blair PS, Fleming P, Hoghton M, Marriott A, Russ L. The confidential inquiry into premature deaths of people with intellectual disabilities in the UK: a population-based study. Lancet. 2014;383:889–95. 10.1016/S0140-6736(13)62026-7 .24332307

21.Baxter H Lowe K Houston H Jones G Felce D Kerr M Previously unidentified morbidity in patients with intellectual disability Br J Gen Pract 2006 56 93 98 16464321 PMC1828252 Baxter H, Lowe K, Houston H, Jones G, Felce D, Kerr M. Previously unidentified morbidity in patients with intellectual disability. Br J Gen Pract. 2006;56:93–8.PMC1828252 16464321

22.Döge J, Hackenberg B, O Brien K, Bohnert A, Rader T, Beutel ME, et al. The Prevalence of Hearing Loss and Provision With Hearing Aids in the Gutenberg Health Study. Dtsch Arztebl Int. 2023;120:99-106. 10.3238/arztebl.m2022.0385 .PMC10132285 36519221

23.Meuwese-Jongejeugd A Vink M van Zanten B Verschuure H Eichhorn E Koopman D Prevalence of hearing loss in 1598 adults with an intellectual disability: cross-sectional population based study Int J Audiol 2006 45 660 669 10.1080/14992020600920812 17118908 Meuwese-Jongejeugd A, Vink M, van Zanten B, Verschuure H, Eichhorn E, Koopman D, et al. Prevalence of hearing loss in 1598 adults with an intellectual disability: cross-sectional population based study. Int J Audiol. 2006;45:660–9. 10.1080/14992020600920812 .17118908

24.Haile LM Kamenov K Briant PS Orji AU Steinmetz JD Abdoli A Hearing loss prevalence and years lived with disability, 1990–2019: findings from the Global Burden of Disease Study 2019 Lancet 1990 397 996 1009 10.1016/S0140-6736(21)00516-X PMC7960691 33714390 Haile LM, Kamenov K, Briant PS, Orji AU, Steinmetz JD, Abdoli A, et al. Hearing loss prevalence and years lived with disability, 1990–2019: findings from the Global Burden of Disease Study 2019. Lancet. 2021;397:996–1009. 10.1016/S0140-6736(21)00516-X .PMC7960691 33714390

25.Zielonkowski S Mathmann P Naghipour A Wasmuth S Prein L Parfitt R Evaluating the hearing-related quality of life in people with intellectual disabilities J Intellect Disabil Res 2025 69 1413 1424 10.1111/jir.70036 40963427 PMC12580484 Zielonkowski S, Mathmann P, Naghipour A, Wasmuth S, Prein L, Parfitt R, et al. Evaluating the hearing-related quality of life in people with intellectual disabilities. J Intellect Disabil Res. 2025;69:1413–24. 10.1111/jir.70036 .PMC12580484 40963427

26.Hild U Hey C Baumann U Montgomery J Euler HA Neumann K High prevalence of hearing disorders at the Special Olympics indicate need to screen persons with intellectual disability J Intellect Disabil Res 2008 52 520 528 10.1111/j.1365-2788.2008.01059.x 18410317 Hild U, Hey C, Baumann U, Montgomery J, Euler HA, Neumann K. High prevalence of hearing disorders at the Special Olympics indicate need to screen persons with intellectual disability. J Intellect Disabil Res. 2008;52:520–8. 10.1111/j.1365-2788.2008.01059.x .18410317

27.Neumann K Dettmer G Euler HA Giebel A Gross M Herer G Auditory status of persons with intellectual disability at the German Special Olympic Games Int J Audiol 2006 45 83 90 10.1080/14992020500376891 16566246 Neumann K, Dettmer G, Euler HA, Giebel A, Gross M, Herer G, et al. Auditory status of persons with intellectual disability at the German Special Olympic Games. Int J Audiol. 2006;45:83–90. 10.1080/14992020500376891 .16566246

28.Willems M Acke F Lannon B Leyssens L Maes L Marks L Global data on ear and hearing screening in an intellectual disability population Am J Intellect Dev Disabil 2022 127 125 134 10.1352/1944-7558-127.2.125 35180777 Willems M, Acke F, Lannon B, Leyssens L, Maes L, Marks L. Global data on ear and hearing screening in an intellectual disability population. Am J Intellect Dev Disabil. 2022;127:125–34. 10.1352/1944-7558-127.2.125 .35180777

29.Manganye SM Frisby C Reddy TM de Kock T Swanepoel DW Hearing loss characteristics and cerumen management efficacy in low-income South African communities: a cross-sectional study Prim Health Care Res Dev 2025 26 e27 10.1017/S1463423625000246 40059819 PMC11955542 Manganye SM, Frisby C, Reddy TM, de Kock T, Swanepoel DW. Hearing loss characteristics and cerumen management efficacy in low-income South African communities: a cross-sectional study. Prim Health Care Res Dev. 2025;26:e27. 10.1017/S1463423625000246 .PMC11955542 40059819

30.World Medical AssociationWorld Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects JAMA 2013 310 2191 2194 10.1001/jama.2013.281053 24141714 World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191–4. 10.1001/jama.2013.281053 .24141714

31.Mathmann P, Gietmann C, Jankovic V, Brannath W, Naghipour A, Matulat P, et al. Hearing Impairments in People With Intellectual Disabilities: A Prospective Cohort Study on Prevalence and Healthcare Utilization. Dtsch Arztebl Int. 2026. Advance online publication. 10.3238/arztebl.m2026.0099 .PMC13599673 42273799

32.World Health Organization. World report on hearing. 2021.

33.Neumann K, Schwalen AS, Gietmann C, Jankovic V, Wasmuth S,Scharpenberg M, et al. Overlooked and undertreated: Hearing loss among individuals with intellectual disabilities - A German cohort study. PLOS Glob Public Health. 2026;6(8):e0006872. 10.1371/journal.pgph.0006872 .PMC13489453 42616729

34.Schwarze K Mathmann P Schäfer K Brannath W Höhne P-H Altin S Effectiveness and costs of a low-threshold hearing screening programme (HörGeist) for individuals with intellectual disabilities: protocol for a screening study BMJ Open 2023 13 e070259 10.1136/bmjopen-2022-070259 37202136 PMC10201260 Schwarze K, Mathmann P, Schäfer K, Brannath W, Höhne P-H, Altin S, et al. Effectiveness and costs of a low-threshold hearing screening programme (HörGeist) for individuals with intellectual disabilities: protocol for a screening study. BMJ Open. 2023;13:e070259. 10.1136/bmjopen-2022-070259 .PMC10201260 37202136

35.Wiegand A Mathmann P Wasmuth S Prein L Parfitt R Scharpenberg M Clinical diagnostics after failed hearing screening in people with intellectual disabilities do not often take place J Intellect Disabil Res 2026 70 384 394 10.1111/jir.70078 41545211 PMC12950632 Wiegand A, Mathmann P, Wasmuth S, Prein L, Parfitt R, Scharpenberg M, et al. Clinical diagnostics after failed hearing screening in people with intellectual disabilities do not often take place. J Intellect Disabil Res. 2026;70:384–94. 10.1111/jir.70078 .PMC12950632 41545211

36.Valderas JM Starfield B Sibbald B Salisbury C Roland M Defining comorbidity: implications for understanding health and health services Ann Fam Med 2009 7 357 363 10.1370/afm.983 19597174 PMC2713155 Valderas JM, Starfield B, Sibbald B, Salisbury C, Roland M. Defining comorbidity: implications for understanding health and health services. Ann Fam Med. 2009;7:357–63. 10.1370/afm.983 .PMC2713155 19597174

37.Tonelli M Wiebe N Lunney M Donald M Howarth T Evans J Associations between hearing loss and clinical outcomes: population-based cohort study EClinicalMedicine 2023 61 102068 10.1016/j.eclinm.2023.102068 37434743 PMC10331811 Tonelli M, Wiebe N, Lunney M, Donald M, Howarth T, Evans J, et al. Associations between hearing loss and clinical outcomes: population-based cohort study. EClinicalMedicine. 2023;61:102068. 10.1016/j.eclinm.2023.102068 .PMC10331811 37434743

38.Wolfram C Schuster AK Elflein HM Nickels S Schulz A Wild PS The Prevalence of Visual Impairment in the Adult Population Dtsch Arztebl Int 2019 116 289 295 10.3238/arztebl.2019.0289 31196384 PMC6584831 Wolfram C, Schuster AK, Elflein HM, Nickels S, Schulz A, Wild PS, et al. The Prevalence of Visual Impairment in the Adult Population. Dtsch Arztebl Int. 2019;116:289–95. 10.3238/arztebl.2019.0289 .PMC6584831 31196384

39.Fellinger J Bertelli MO Deb S Munir K Hassiotis A Salvador-Carulla L Intellectual disability and sensory impairment Textbook of psychiatry for intellectual disability and autism spectrum disorder 2022 ChamSpringer International Publishing849 867 10.1007/978-3-319-95720-3_33 Fellinger J. Intellectual disability and sensory impairment. In: Bertelli MO, Deb S, Munir K, Hassiotis A, Salvador-Carulla L, editors. Textbook of psychiatry for intellectual disability and autism spectrum disorder. Cham: Springer International Publishing; 2022. p. 849–67. 10.1007/978-3-319-95720-3_33 .

40.Fellinger J Holzinger D Dirmhirn A van Dijk J Goldberg D Failure to detect deaf-blindness in a population of people with intellectual disability J Intellect Disabil Res 2009 53 874 881 10.1111/j.1365-2788.2009.01205.x 19694897 Fellinger J, Holzinger D, Dirmhirn A, van Dijk J, Goldberg D. Failure to detect deaf-blindness in a population of people with intellectual disability. J Intellect Disabil Res. 2009;53:874–81. 10.1111/j.1365-2788.2009.01205.x .19694897

41.van den Broek EGC Janssen CGC van Ramshorst T Deen L Visual impairments in people with severe and profound multiple disabilities: an inventory of visual functioning J Intellect Disabil Res 2006 50 470 475 10.1111/j.1365-2788.2006.00804.x 16672040 van den Broek EGC, Janssen CGC, van Ramshorst T, Deen L. Visual impairments in people with severe and profound multiple disabilities: an inventory of visual functioning. J Intellect Disabil Res. 2006;50:470–5. 10.1111/j.1365-2788.2006.00804.x .16672040

42.van Splunder J Stilma JS Bernsen RMD Evenhuis HM Prevalence of visual impairment in adults with intellectual disabilities in the Netherlands: cross-sectional study Eye (Lond) 2006 20 1004 1010 10.1038/sj.eye.6702059 16151486 van Splunder J, Stilma JS, Bernsen RMD, Evenhuis HM. Prevalence of visual impairment in adults with intellectual disabilities in the Netherlands: cross-sectional study. Eye (Lond). 2006;20:1004–10. 10.1038/sj.eye.6702059 .16151486

43.Pradeep A, Brugha T, Kiani R. #7171 Adults with intellectual disability: what do we know about visual and hearing impairments? A cross-sectional analysis. In: The BNPA 37th Annual Conference, ‘How do our Situations and Environment Shape Us’. BMJ Publishing Group Ltd; 2024. p. 022025. A12.2-A12. 10.1136/JNNP-2024-BNPA.25 .

44.Schott JW Huang P Morgan M Nelson-Brantley J Koehler A Renslo B Third-generation lentiviral gene therapy rescues function in a mouse model of Usher 1B Mol Ther 2023 31 3502 3519 10.1016/j.ymthe.2023.10.018 37915173 PMC10727968 Schott JW, Huang P, Morgan M, Nelson-Brantley J, Koehler A, Renslo B, et al. Third-generation lentiviral gene therapy rescues function in a mouse model of Usher 1B. Mol Ther. 2023;31:3502–19. 10.1016/j.ymthe.2023.10.018 .PMC10727968 37915173

45.Hoppen T Bestandsaufnahme gut 150 Jahre nach der Erstbeschreibung Pädiatrie 2021 33 40 45 10.1007/s15014-020-3657-2 Hoppen T. Bestandsaufnahme gut 150 Jahre nach der Erstbeschreibung. Pädiatrie. 2021;33:40–5. 10.1007/s15014-020-3657-2 .

46.Bower C Leonard H Petterson B Intellectual disability in Western Australia J Paediatr Child Health 2000 36 213 215 10.1046/j.1440-1754.2000.00480.x 10849218 Bower C, Leonard H, Petterson B. Intellectual disability in Western Australia. J Paediatr Child Health. 2000;36:213–5. 10.1046/j.1440-1754.2000.00480.x .10849218

47.Ramia M Musharrafieh U Khaddage W Sabri A Revisiting Down syndrome from the ENT perspective: review of literature and recommendations Eur Arch Otorhinolaryngol 2014 271 863 869 10.1007/s00405-013-2563-4 23689804 Ramia M, Musharrafieh U, Khaddage W, Sabri A. Revisiting Down syndrome from the ENT perspective: review of literature and recommendations. Eur Arch Otorhinolaryngol. 2014;271:863–9. 10.1007/s00405-013-2563-4 .23689804

48.Tateossian H, Southern A, Vikhe P, Lana-Elola E, Watson-Scales S, Gibbins D, et al. DYRK1A kinase triplication is the major cause of Otitis Media in Down Syndrome. 2025;eLife14:RP101969. 10.7554/eLife.101969.1 .

49.Gu L Guo W Wang X Yue C The association between thyroid disease and hearing loss: a meta-analysis Acta Otolaryngol 2024 144 495 502 10.1080/00016489.2024.2404614 39356749 Gu L, Guo W, Wang X, Yue C. The association between thyroid disease and hearing loss: a meta-analysis. Acta Otolaryngol. 2024;144:495–502. 10.1080/00016489.2024.2404614 .39356749

50.Richter C-P Münscher A Machado DS Wondisford FE Ortiga-Carvalho TM Complete activation of thyroid hormone receptor β by T3 is essential for normal cochlear function and morphology in mice Cell Physiol Biochem 2011 28 997 1008 10.1159/000335812 22178950 PMC3709180 Richter C-P, Münscher A, Machado DS, Wondisford FE, Ortiga-Carvalho TM. Complete activation of thyroid hormone receptor β by T3 is essential for normal cochlear function and morphology in mice. Cell Physiol Biochem. 2011;28:997–1008. 10.1159/000335812 .PMC3709180 22178950

51.Rusch A Ng L Goodyear R Oliver D Lisoukov I Vennstrom B Retardation of cochlear maturation and impaired hair cell function caused by deletion of all known thyroid hormone receptors J Neurosci 2001 21 9792 9800 10.1523/JNEUROSCI.21-24-09792.2001 11739587 PMC6763054 Rusch A, Ng L, Goodyear R, Oliver D, Lisoukov I, Vennstrom B, et al. Retardation of cochlear maturation and impaired hair cell function caused by deletion of all known thyroid hormone receptors. J Neurosci. 2001;21:9792–800. 10.1523/JNEUROSCI.21-24-09792.2001 .PMC6763054 11739587

52.Jin Y, Li S, Zhang Q, Guo B, Xiong Y, Hu Y, et al. The Role of Thyroid Hormone Signaling in the Development and Pathophysiology of Hearing: From Molecular Mechanisms to Clinical Applications. Int J Mol Sci 2026. 10.3390/ijms27052196 .PMC12984108 41828421

53.O’Malley BW Li D Turner DS Hearing loss and cochlear abnormalities in the congenital hypothyroid (hyt/hyt) mouse Hear Res 1995 88 181 189 10.1016/0378-5955(95)00111-g 8575993 O’Malley BW, Li D, Turner DS. Hearing loss and cochlear abnormalities in the congenital hypothyroid (hyt/hyt) mouse. Hear Res. 1995;88:181–9. 10.1016/0378-5955(95)00111-g .8575993

54.Strzelczyk A Margraf NG Faber SC Fulgeri N Schulze-Bonhage A Demographics and care of epilepsy in older adults in Germany Seizure 2025 128 4 15 10.1016/j.seizure.2025.02.003 40050190 Strzelczyk A, Margraf NG, Faber SC, Fulgeri N, Schulze-Bonhage A. Demographics and care of epilepsy in older adults in Germany. Seizure. 2025;128:4–15. 10.1016/j.seizure.2025.02.003 .40050190

55.Weih M Köhler S Schöll N Schulz M Hering R Mental, Neurological, and Somatic Comorbidities and Their Treatment in Persons With Intellectual Disability Dtsch Arztebl Int 2022 119 418 414 10.3238/arztebl.m2022.0193 35506265 PMC9533706 Weih M, Köhler S, Schöll N, Schulz M, Hering R. Mental, Neurological, and Somatic Comorbidities and Their Treatment in Persons With Intellectual Disability. Dtsch Arztebl Int. 2022;119:418–414. 10.3238/arztebl.m2022.0193 .PMC9533706 35506265

56.Halladay AK Bishop S Constantino JN Daniels AM Koenig K Palmer K Sex and gender differences in autism spectrum disorder: summarizing evidence gaps and identifying emerging areas of priority Mol Autism 2015 6 36 10.1186/s13229-015-0019-y 26075049 PMC4465158 Halladay AK, Bishop S, Constantino JN, Daniels AM, Koenig K, Palmer K, et al. Sex and gender differences in autism spectrum disorder: summarizing evidence gaps and identifying emerging areas of priority. Mol Autism. 2015;6:36. 10.1186/s13229-015-0019-y .PMC4465158 26075049

57.Zeidan J Fombonne E Scorah J Ibrahim A Durkin MS Saxena S Global prevalence of autism: a systematic review update Autism Res 2022 15 778 790 10.1002/aur.2696 35238171 PMC9310578 Zeidan J, Fombonne E, Scorah J, Ibrahim A, Durkin MS, Saxena S, et al. Global prevalence of autism: a systematic review update. Autism Res. 2022;15:778–90. 10.1002/aur.2696 .PMC9310578 35238171

58.Giambattista C Ventura P Trerotoli P Margari F Margari L Sex differences in autism spectrum disorder: focus on high functioning children and adolescents Front Psychiatry 2021 12 539835 10.3389/fpsyt.2021.539835 34305658 PMC8298903 Giambattista C, Ventura P, Trerotoli P, Margari F, Margari L. Sex differences in autism spectrum disorder: focus on high functioning children and adolescents. Front Psychiatry. 2021;12:539835. 10.3389/fpsyt.2021.539835 .PMC8298903 34305658

59.Violan C Foguet-Boreu Q Flores-Mateo G Salisbury C Blom J Freitag M Prevalence, determinants and patterns of multimorbidity in primary care: a systematic review of observational studies PLoS One 2014 9 e102149 10.1371/journal.pone.0102149 25048354 PMC4105594 Violan C, Foguet-Boreu Q, Flores-Mateo G, Salisbury C, Blom J, Freitag M, et al. Prevalence, determinants and patterns of multimorbidity in primary care: a systematic review of observational studies. PLoS One. 2014;9:e102149. 10.1371/journal.pone.0102149 .PMC4105594 25048354

60.Skou ST Mair FS Fortin M Guthrie B Nunes BP Miranda JJ Multimorbidity Nat Rev Dis Primers 2022 8 48 10.1038/s41572-022-00376-4 35835758 PMC7613517 Skou ST, Mair FS, Fortin M, Guthrie B, Nunes BP, Miranda JJ, et al. Multimorbidity. Nat Rev Dis Primers. 2022;8:48. 10.1038/s41572-022-00376-4 .PMC7613517 35835758

61.Schoufour JD Oppewal A van der Maarl HJK Hermans H Evenhuis HM Hilgenkamp TIM Festen DA Multimorbidity and polypharmacy are independently associated with mortality in older people with intellectual disabilities: a 5-year follow-up from the HA-ID study Am J Intellect Dev Disabil 2018 123 72 82 10.1352/1944-7558-123.1.72 29281324 Schoufour JD, Oppewal A, van der Maarl HJK, Hermans H, Evenhuis HM, Hilgenkamp TIM, et al. Multimorbidity and polypharmacy are independently associated with mortality in older people with intellectual disabilities: a 5-year follow-up from the HA-ID study. Am J Intellect Dev Disabil. 2018;123:72–82. 10.1352/1944-7558-123.1.72 .29281324

62.Savvas E, Dimitrakopoulou E, Euler HA, Coninx F, Bluemel F, Krieger A, et al. Hearing Threshold Estimation With Distortion Product Otoacoustic Emission Growth Functions in People With Intellectual Disabilities in an Outreach Setting. JIntellect Disabil Res. 2025. 69(12):1474-85. 10.1111/jir.70043 .PMC12580478 40976998

63.Erickson K Quick N The profiles of students with significant cognitive disabilities and known hearing loss J Deaf Stud Deaf Educ 2017 22 35 48 10.1093/deafed/enw052 27599868 PMC6279204 Erickson K, Quick N. The profiles of students with significant cognitive disabilities and known hearing loss. J Deaf Stud Deaf Educ. 2017;22:35–48. . 10.1093/deafed/enw052 PMC6279204 27599868

64.Naghipour A Becher E Gemander M Oertelt-Prigione S Designing clinical practice guidelines for equitable, inclusive, and contextualised care BMJ 2025 391 e085684 10.1136/bmj-2025-085684 41073077 PMC12509990 Naghipour A, Becher E, Gemander M, Oertelt-Prigione S. Designing clinical practice guidelines for equitable, inclusive, and contextualised care. BMJ. 2025;391:e085684. 10.1136/bmj-2025-085684 .PMC12509990 41073077

65.Santambrogio J Masi G Bertelli MO Attention deficit hyperactivity disorder in adults with intellectual disability: report 230 of the Royal College of Psychiatrists J Ment Health Res Intellect Disabil 2021 14 344 348 10.1080/19315864.2021.1942599 Santambrogio J, Masi G, Bertelli MO. Attention deficit hyperactivity disorder in adults with intellectual disability: report 230 of the Royal College of Psychiatrists. J Ment Health Res Intellect Disabil. 2021;14:344–8. 10.1080/19315864.2021.1942599 .

66.Santambrogio J Bertelli MO Terrevazzi S de Carolis L Francia E Boldoni C Cognitive dysfunction and psychopathology: a cohort study of adults with intellectual developmental disorder J Intellect Disabil Res 2023 67 1029 1045 10.1111/jir.13077 37690814 Santambrogio J, Bertelli MO, Terrevazzi S, de Carolis L, Francia E, Boldoni C, et al. Cognitive dysfunction and psychopathology: a cohort study of adults with intellectual developmental disorder. J Intellect Disabil Res. 2023;67:1029–45. 10.1111/jir.13077 .37690814

67.Santambrogio J Colmegna F Di Brita C Merra A Bertelli MO Clerici M Percorso psichiatrico e psicologico per una giovane donna con sindrome da delezione del cromosoma 22 e disabilità intellettiva: un buon outcome. [Psychiatric and psychological support for an adolescent woman with chromosome 22 deletion syndrome and intellectual disability: a good outcome] Riv Psichiatr. 2020 55 106 11 10.1708/3333.33025 32202548 Santambrogio J, Colmegna F, Di Brita C, Merra A, Bertelli MO, Clerici M. Percorso psichiatrico e psicologico per una giovane donna con sindrome da delezione del cromosoma 22 e disabilità intellettiva: un buon outcome. [Psychiatric and psychological support for an adolescent woman with chromosome 22 deletion syndrome and intellectual disability: a good outcome]. Riv Psichiatr. 2020;55:106–11. 10.1708/3333.33025 .32202548

68.de Vaan G Vervloed MPJ Peters-Scheffer NC van Gent T Knoors H Verhoeven L Assessing Autism Spectrum Disorder in People with Sensory Impairments Combined with Intellectual Disabilities J Dev Phys Disabil 2018 30 471 487 10.1007/s10882-018-9597-x 30100694 PMC6061084 de Vaan G, Vervloed MPJ, Peters-Scheffer NC, van Gent T, Knoors H, Verhoeven L. Assessing Autism Spectrum Disorder in People with Sensory Impairments Combined with Intellectual Disabilities. J Dev Phys Disabil. 2018;30:471–87. 10.1007/s10882-018-9597-x .PMC6061084 30100694

69.Sun JJ Perera B Henley W Angus-Leppan H Sawhney I Watkins L Epilepsy related multimorbidity, polypharmacy and risks in adults with intellectual disabilities: a national study J Neurol 2022 269 2750 2760 10.1007/s00415-021-10938-3 35067759 Sun JJ, Perera B, Henley W, Angus-Leppan H, Sawhney I, Watkins L, et al. Epilepsy related multimorbidity, polypharmacy and risks in adults with intellectual disabilities: a national study. J Neurol. 2022;269:2750–60. 10.1007/s00415-021-10938-3 .35067759

70.Komenda-Schned S Landskron SJ Moritz P Brunevskaya N Santambrogio J Salvador-Carulla L Good mental health in people with intellectual disabilities: a systematic review Health Psychol Rev 2024 18 954 976 10.1080/17437199.2024.2398021 39260434 Komenda-Schned S, Landskron SJ, Moritz P, Brunevskaya N, Santambrogio J, Salvador-Carulla L, et al. Good mental health in people with intellectual disabilities: a systematic review. Health Psychol Rev. 2024;18:954–76. 10.1080/17437199.2024.2398021 .39260434

71.Janz HL Ableism: the undiagnosed malady afflicting medicine CMAJ 2019 191 E478 E479 10.1503/cmaj.180903 31036612 PMC6488478 Janz HL. Ableism: the undiagnosed malady afflicting medicine. CMAJ. 2019;191:E478–9. 10.1503/cmaj.180903 .PMC6488478 31036612

Come citare questo studio

Awa Naghipour, Corinna Gietmann, Vincent Jankovic, Martin Scharpenberg, Susanna Marie Zielonkowski, Lukas Prein, Katharina Schwarze, Anja Neumann, Susanne Wasmuth, Karolin Schäfer, Christian Speckemeier, Sarah Schlierenkamp, Sandra Werner, Ross Parfitt, Anna Wiegand, Anna-Sophia Schwalen, Werner Brannath, Philipp Mathmann, Katrin Neumann. (2026). Comorbidities in individuals with intellectual disabilities with and without hearing loss: a prospective cohort study.. BMC public health. DOI: 10.1186/s12889-026-29321-w

Consulta la pubblicazione originale ↗